

Ticker: **PFE US EQUITY**

**Pfizer Inc (New York: PFE, Currency: USD)**

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Website	www.pfizer.com
Number of Employees	81,000
Ticker:	PFE US

66 Hudson Blvd East New York, NY 10001 United States
Phone : 1-212-733-2323
Fax : 1-212-573-7851

↑ **25.30** +0.02


Pfizer Inc. opera como una empresa farmacéutica. Ofrece medicamentos, vacunas, dispositivos médicos y productos sanitarios de consumo para los sectores de oncología, inflamación, cardiovascular y otros de terapia. Atiende a clientes en todo el mundo.

**Stock Quote & Chart (Currency: USD)**

Last (delayed quote)	25.30	Market Cap (MM)	143,820.0
Open	25.18	Shares Out. (MM)	5,685.7
Previous Close	25.28	Float %	100.0%
Change	-0.15	Shares sold short (MM)	139,486,093.0
Change %	-0.59	Dividend Yield %	6.8
Day High/Day Low	25.6 / 25.1	Diluted EPS Excl. XO	
52 Wk High/52 Wk low	27.7 / 20.9	P / Diluted EPS Before XO	
Volume (MM)	15.58	Beta	0.61
Avg. Vol - 3 mo (MM)	63.21		

**Financial Information (Currency: USD, in mm)**

Revenue - LTM	62,785.0	Cash & ST Invst.	20,477
EBIT - LTM	13,720.0	Total Assets	213,396.0
EBITDA - LTM	20,416.0	Total Debt	66,993.0
Net Income - LTM	9,828.0	Total Liabilities	124,899.0
Total Enterprise Value	190,844	Total Equity	88,497.0
TEV/ Total Revenue	2.9 x	Cash from Operations - LTM	13,077.0
TEV/ EBITDA	8.9 x	Cash from Investing - LTM	3,172.0
		Cash from Financing -LTM	-14,213.0



**Company Notes**

2015 Q3	GAAP Net Income Includes: (in millions, pre-tax) A loss of \$470.000 from Asset Write Down A loss of \$529.000 from Restructuring A loss of \$163.000 from Impairment of Intangibles A loss of \$124.000 from Merger & Acquisition. A gain of \$35.000 from Disposal of assets. A loss of 92.000 from various one time items.	A gain of \$35.000 from Disposal of assets. A loss of 92.000 from various one time items.
2015 Q2	GAAP Net Income Includes: (in millions, pre-tax) A loss of \$304.000 from Other One Time Items A loss of \$25.000 from Asset Write Down A loss of \$68.000 from Merger/Acquisition Expense A gain of \$ 5.000 from Investments, a gain from \$ 15.000 from disposal of asset, A loss of \$25.000 from impairment of asset	2015 Q2 GAAP Net Income Includes: (in millions, pre-tax) A loss of \$304.000 from Other One Time Items A loss of \$25.000 from Asset Write Down A loss of \$68.000 from Merger/Acquisition Expense A gain of \$ 5.000 from Investments, a gain from \$ 15.000 from disposal of asset, A loss of \$25.000 from impairment of asset
2015 Q1	GAAP Net Income includes, (in millions, after-tax): a loss of \$17.000 from Acquisition/Merger a loss of \$167.000 from Various One-Time Items a gain of \$5.000 from Discontinued Operations	2015 Q1 GAAP Net Income includes, (in millions, after-tax): a loss of \$17.000 from Acquisition/Merger a loss of \$167.000 from Various One-Time Items a gain of \$5.000 from Discontinued Operations
2014 A1	GAAP Net Income includes, (in millions): a pre-tax gain of \$288.000 from Disposal of Assets a pre-tax loss of \$1,630.000 from Impairment/Legal a pre-tax loss of \$250.000 from Restructuring/Acquisition an after-tax gain of \$48.000 from Discontinued Operations	2014 A1 GAAP Net Income includes, (in millions): a pre-tax gain of \$288.000 from Disposal of Assets a pre-tax loss of \$1,630.000 from Impairment/Legal a pre-tax loss of \$250.000 from Restructuring/Acquisition an after-tax gain of \$48.000 from Discontinued Operations

**Key Board Members**

Name	Title	Organization
Ronald E Blaylock "Ron"	Founder Partner/Founder Board Member Board Member Board Member	Blaylock & Partners Lp Gennx360 Capital Partners Pfizer Inc Wr Berkley Corp Mebane Charitable Foundation I
Susan Desmond-Hellmann "Sue"	Board Member Board Member Board Member Board Member Board Member	Openai Inc Pfizer Inc National Resilience Inc Pfizer Venture Investments
Suzanne Nora Johnson	Co-Chairman Board Member Trustee Chairman Trustee Trustee Board Member Board Member Board Member Board Member Chairman	Brookings Institution/The Pfizer Inc University Of Southern Califor John & Mary R Markle Foundatio Carnegie Institution Of Washin University Of Southern Califor Visa Intl Inc Women'S World Banking Inc Technoserve Inc Council For Excellence In Govt American Red Cross Children Now Inc Intuit Inc
Shantanu Narayen	Co-Founder Chairman/President/Ceo Chair/Ceo Lead Director Vice Chairman Chairman	Pictra Inc Adobe Ventures Lp Adobe Inc Pfizer Inc Us-India Strategic Partnership Adobe Foundation
Susan Hockfield	Overseer	Boston Symphony Orchestra Inc

Ticker: PFE US EQUITY

Pfizer Inc


Period Type: Annuals

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Annuals	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	0FY	-0fs	1FY	2FY	3FY
<b>Key Financials</b>											
	Actuals							LTM	Estimates		
For the Fiscal Period Ending	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022	31/12/2023	28/09/2025	28/09/2025	31/12/2025	31/12/2026	31/12/2027
Currency	USD										
Pfizer Inc. opera como una empresa farmacéutica. Ofrece medicamentos, vacunas, dispositivos médicos y productos sanitarios de consumo para los sectores de											
Total Revenue	53,647.0	40,905.0	41,651.0	81,288.0	100,330.0	59,554.0	63,627.0	46,928.0	63,627.0	17,041.3	17,041.3
Growth Over Prior Year	2.1%	(23.8%)	1.8%	95.2%	23.4%	(40.6%)	6.8%	--	(4.1%)	(4.1%)	(4.1%)
Gross Profit	42,399.0	32,851.0	33,167.0	50,467.0	65,986.0	34,600.0	45,776.0	--	--	--	--
Margin %	79.0%	80.3%	79.6%	62.1%	65.8%	58.1%	71.9%	--	--	--	--
EBITDA	20,385.0	20,948.0	13,329.0	25,131.0	40,690.0	8,409.0	20,084.0	--	5,665.5	5,665.5	5,665.5
Margin %	38.0%	51.2%	32.0%	30.9%	40.6%	14.1%	31.6%	--	8.9%	33.2%	33.2%
EBIT	14,001.0	14,817.0	8,256.0	19,433.0	34,944.0	1,280.0	12,411.0	--	4,277.8	4,277.8	4,277.8
Margin %	26.1%	36.2%	19.8%	23.9%	34.8%	2.1%	19.5%	--	6.7%	25.1%	25.1%
Earnings from Cont. Ops.	11,179.0	10,738.0	6,666.0	22,459.0	31,401.0	2,173.0	8,051.0	--	--	--	--
Margin %	20.8%	26.3%	16.0%	27.6%	31.3%	3.6%	12.7%	--	--	--	--
Net Income	11,153.0	16,026.0	9,159.0	21,979.0	31,372.0	2,119.0	8,031.0	--	3,221.6	3,221.6	3,221.6
Margin %	20.8%	39.2%	22.0%	27.0%	31.3%	3.6%	12.6%	--	5.1%	18.9%	18.9%
Diluted EPS Excl. Extra Items	1.9	1.9	1.2	3.9	5.5	0.4	1.4	--	0.6	0.6	0.6
Growth Over Prior Year	(47.2%)	1.6%	(37.6%)	233.1%	39.2%	(93.2%)	281.1%	--	(9.5%)	(9.5%)	(9.5%)

Current Capitalization (Millions)

Currency	USD
Share Price (USD)	25.30
Shares Out.	5,685.71
Market Capitalization (USD)	143,820.54
- Cash & Short Term Investments	0.00
+ Total Debt	0.00
+ Pref. Equity	0.00
+ Total Minority Interest	0.00
= Total Enterprise Value (USD)	190,843.54
Book Value of Common Equity	0.00
+ Pref. Equity	0.00
+ Total Minority Interest	0.00
+ Total Debt	0.00
= Total Capital	0.00




PE Ratio

Valuation Multiples based on Current Capitalization

For the Fiscal Period Ending	Actual	LTM	Estimates	
	28/09/2025	28/09/2025	28/09/2025	28/09/2025
TEV/Total Revenue	3.1x	--	11.1x	11.1x
TEV/EBITDA	9.8x	--	--	--
TEV/EBIT	15.7x	--	9.0x	9.0x
P/Diluted EPS Before Extra	18.8x	--	--	--
P/BV	1.7x	--	--	--
Price/Tang BV	--	--	--	--

Valuation Multiples for Chart

For the Fiscal Period Ending	TTM	FY1	NTM	FY2
PE Ratio	9.4x	8.7x	8.7x	8.7x
TEV / EBITDA	8.9x	0.0x	0.0x	0.0x
Price / CF	11.0x	0.0x	0.0x	0.0x
Price / Book	1.5x	0.0x	0.0x	0.0x
Dividend Yield	6.8x	6.8x	6.8x	6.8x



Ticker:	PFE US EQUITY	PFE US EQUITY	Ascend	Currency	Reporting	Change	USD
Period Type	Annuals	Consolidated	Yes	Accounting	Mixed		

## Pfizer Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	0FY
<b>Income Statement</b>											
Income Sheet as of:	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022	31/12/2023	31/12/2024
Currency	USD	USD	USD								
Revenue	49,605.00	48,851.00	52,824.00	52,546.00	53,647.00	40,905.00	41,651.00	81,288.00	91,793.00	51,972.00	55,239.00
Other Revenue	-	-	-	-	-	-	-	-	8,537.00	7,582.00	8,388.00
<b>Total Revenue</b>	<b>49,605.00</b>	<b>48,851.00</b>	<b>52,824.00</b>	<b>52,546.00</b>	<b>53,647.00</b>	<b>40,905.00</b>	<b>41,651.00</b>	<b>81,288.00</b>	<b>100,330.00</b>	<b>59,554.00</b>	<b>63,627.00</b>
Cost Of Goods Sold	9,577.00	9,648.00	12,329.00	11,228.00	11,248.00	8,054.00	8,484.00	30,821.00	34,344.00	24,954.00	17,851.00
<b>Gross Profit</b>	<b>40,028.00</b>	<b>39,203.00</b>	<b>40,495.00</b>	<b>41,318.00</b>	<b>42,399.00</b>	<b>32,851.00</b>	<b>33,167.00</b>	<b>50,467.00</b>	<b>65,986.00</b>	<b>34,600.00</b>	<b>45,776.00</b>
Selling General & Admin Exp.	14,347.00	15,961.00	16,561.00	15,155.00	15,499.00	5,220.00	12,170.00	16,974.00	16,005.00	22,641.00	22,543.00
R & D Exp.	8,393.00	7,690.00	7,872.00	7,683.00	8,006.00	8,385.00	9,393.00	10,360.00	11,428.00	10,679.00	10,822.00
Depreciation & Amort.	4,039.00	3,728.00	4,056.00	4,758.00	4,893.00	4,429.00	3,348.00	3,700.00	3,609.00	-	-
Other Operating Expense/(Income)	-	-	-	-	-	-	-	-	-	-	-
<b>Operating Expense, Total</b>	<b>26,779.00</b>	<b>27,379.00</b>	<b>28,489.00</b>	<b>27,596.00</b>	<b>28,398.00</b>	<b>18,034.00</b>	<b>24,911.00</b>	<b>31,034.00</b>	<b>31,042.00</b>	<b>33,320.00</b>	<b>33,365.00</b>
<b>Operating Income</b>	<b>13,249.00</b>	<b>11,824.00</b>	<b>12,006.00</b>	<b>13,722.00</b>	<b>14,001.00</b>	<b>14,817.00</b>	<b>8,256.00</b>	<b>19,433.00</b>	<b>34,944.00</b>	<b>1,280.00</b>	<b>12,411.00</b>
Interest Expense	1,360.00	1,199.00	1,186.00	1,270.00	1,316.00	1,573.00	1,449.00	1,291.00	1,238.00	2,209.00	3,091.00
Interest Income	425.00	471.00	470.00	391.00	333.00	225.00	73.00	36.00	251.00	1,624.00	545.00
<b>Net Interest Exp.</b>	<b>935.00</b>	<b>728.00</b>	<b>716.00</b>	<b>879.00</b>	<b>983.00</b>	<b>1,348.00</b>	<b>1,376.00</b>	<b>1,255.00</b>	<b>987.00</b>	<b>585.00</b>	<b>2,546.00</b>
Currency Exchange Gains (Loss)	-	806.00	-	-	-	-	-	-	-	-	-
Other Non-Operating Inc. (Exp.)	74.00	1,325.00	2,939.00	538.00	1,133.00	2,148.00	(156.00)	(6,133.00)	(772.00)	(363.00)	1,842.00
<b>EBT Excl. Unusual Items</b>	<b>12,240.00</b>	<b>8,965.00</b>	<b>8,351.00</b>	<b>12,305.00</b>	<b>11,885.00</b>	<b>11,321.00</b>	<b>7,036.00</b>	<b>24,311.00</b>	<b>34,729.00</b>	<b>1,058.00</b>	<b>8,023.00</b>
Impairment of Goodwill	-	-	-	-	-	-	-	-	-	-	-
Gain (Loss) On Sale Of Assets	-	-	-	-	-	-	-	-	-	-	-
Asset Writedown	-	-	-	-	-	-	-	-	-	-	-
Legal Settlements	-	-	-	-	-	-	-	-	-	-	-
Other Unusual Items	-	-	-	-	-	-	-	-	-	-	-
<b>EBT Incl. Unusual Items</b>	<b>12,240.00</b>	<b>8,965.00</b>	<b>8,351.00</b>	<b>12,305.00</b>	<b>11,885.00</b>	<b>11,321.00</b>	<b>7,036.00</b>	<b>24,311.00</b>	<b>34,729.00</b>	<b>1,058.00</b>	<b>8,023.00</b>
Income Tax Expense	3,120.00	1,990.00	1,123.00	(9,048.00)	706.00	583.00	370.00	1,852.00	3,328.00	(1,115.00)	(28.00)
<b>Earnings from Cont. Ops.</b>	<b>9,120.00</b>	<b>6,975.00</b>	<b>7,228.00</b>	<b>21,353.00</b>	<b>11,179.00</b>	<b>10,738.00</b>	<b>6,666.00</b>	<b>22,459.00</b>	<b>31,401.00</b>	<b>2,173.00</b>	<b>8,051.00</b>
Extraord. Item & Account. Change	(48.00)	(11.00)	(18.00)	(2.00)	(10.00)	(5,318.00)	(2,529.00)	434.00	(6.00)	15.00	(11.00)
Minority Int. in Earnings	33.00	26.00	31.00	47.00	36.00	30.00	36.00	46.00	35.00	39.00	31.00
<b>Net Income</b>	<b>9,135.00</b>	<b>6,960.00</b>	<b>7,215.00</b>	<b>21,308.00</b>	<b>11,153.00</b>	<b>16,026.00</b>	<b>9,159.00</b>	<b>21,979.00</b>	<b>31,372.00</b>	<b>2,119.00</b>	<b>8,031.00</b>
Pref. Dividends	2.00	2.00	2.00	1.00	1.00	-	-	-	-	-	-
Other Adj	-	-	-	-	-	-	-	-	-	-	-
<b>NI to Common Incl Extra Items</b>	<b>9,133.00</b>	<b>6,958.00</b>	<b>7,213.00</b>	<b>21,307.00</b>	<b>11,152.00</b>	<b>16,026.00</b>	<b>9,159.00</b>	<b>21,979.00</b>	<b>31,372.00</b>	<b>2,119.00</b>	<b>8,031.00</b>
Abnormal Losses (Gains)	3,618.00	5,369.00	8,789.00	2,554.00	3,429.00	(2,791.00)	4,947.00	2,496.00	5,299.00	6,137.00	6,664.00
Tax Effect on Abnormal Items	(1,266.30)	(1,879.15)	(3,076.15)	(11,396.54)	(1,049.67)	(813.89)	(949.34)	(1,406.35)	(1,129.06)	(1,266.11)	(1,587.07)
<b>NI to Common Excl. Extra Items</b>	<b>11,484.70</b>	<b>10,447.85</b>	<b>12,925.85</b>	<b>12,464.46</b>	<b>13,531.33</b>	<b>12,421.11</b>	<b>13,156.66</b>	<b>23,068.65</b>	<b>35,541.94</b>	<b>6,989.89</b>	<b>13,107.93</b>
<b>Per Share Items</b>											
Basic EPS	1.44	1.13	1.18	3.57	1.90	2.88	1.65	3.92	5.59	0.38	1.42
Basic EPS Excl. Extra Items	1.43	1.13	1.18	3.57	1.90	1.92	1.19	4.00	5.59	0.38	1.42
Weighted Avg. Basic Shares Out.	6,346.00	6,176.00	6,089.00	5,970.00	5,872.00	5,569.00	5,555.00	5,601.00	5,608.00	5,643.00	5,664.00
Diluted EPS	1.42	1.11	1.17	3.52	1.87	2.82	1.63	3.85	5.47	0.37	1.41
Diluted EPS Excl. Extra Items	1.41	1.11	1.17	3.52	1.86	1.89	1.18	3.93	5.47	0.37	1.41
Weighted Avg. Diluted Shares Out.	6,424.00	6,257.00	6,159.00	6,058.00	5,977.00	5,675.00	5,632.00	5,708.00	5,733.00	5,709.00	5,700.00
Normalized Basic EPS	2.26	2.20	2.40	2.65	3.00	2.95	2.22	-	6.58	1.85	3.12
Normalized Diluted EPS	1.78	1.67	2.10	2.06	2.26	1.25	1.89	4.12	6.20	1.22	2.30
Dividends per Share	-	-	-	-	-	-	-	-	-	-	-
Payout Ratio %	72.65	99.57	101.55	36.43	72.73	75.93	128.19	39.33	28.81	436.55	119.41
<b>Supplemental Items</b>											
EBITA	17,288.00	15,552.00	16,062.00	18,480.00	18,894.00	15,193.00	11,996.00	23,640.00	39,235.00	6,852.00	18,357.00
EBIT	13,249.00	11,824.00	12,006.00	13,722.00	14,001.00	14,817.00	8,256.00	19,433.00	34,944.00	1,280.00	12,411.00
As Reported Total Revenue*	49,605.00	48,851.00	52,824.00	52,546.00	53,647.00	40,905.00	41,651.00	81,288.00	100,330.00	59,554.00	63,627.00
Effective Tax Rate %	25.49	22.20	13.45	-	5.94	5.15	5.26	7.62	9.58	-	-
Normalized Net Income	11,436.70	10,436.85	12,907.85	12,462.46	13,521.33	7,103.11	10,627.66	23,502.65	35,535.94	7,004.89	13,096.93
Interest Capitalized	41.00	32.00	61.00	72.00	73.00	88.00	96.00	108.00	124.00	160.00	182.00
<b>Supplemental Operating Expense Items</b>											
Net Rental Exp.	-	-	-	-	-	-	-	-	-	-	-
Stock-Based Comp., Unallocated	586.00	669.00	691.00	840.00	949.00	687.00	755.00	1,182.00	872.00	525.00	877.00
<b>Stock-Based Comp., Total</b>	<b>586.00</b>	<b>669.00</b>	<b>691.00</b>	<b>840.00</b>	<b>949.00</b>	<b>687.00</b>	<b>755.00</b>	<b>1,182.00</b>	<b>872.00</b>	<b>525.00</b>	<b>877.00</b>

Ticker:	PFE US EQUITY
Period Type	Annuals

PFE US EQUITY	Ascend
Consolidated	Yes

Currency	Reporting	Change	USD
Accounting	Mixed		

## Pfizer Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
<b>Balance Sheet</b>											
Balance Sheet as of:	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022	31/12/2023	31/12/2024
Currency	USD										
<b>ASSETS</b>											
Cash And Equivalents	3,343.00	3,641.00	2,595.00	1,342.00	1,139.00	1,121.00	1,786.00	1,944.00	416.00	2,853.00	1,043.00
Short Term Investments	32,779.00	19,649.00	15,255.00	18,650.00	17,694.00	8,525.00	10,437.00	29,125.00	22,316.00	9,837.00	19,434.00
<b>Total Cash &amp; ST Investments</b>	<b>36,122.00</b>	<b>23,290.00</b>	<b>17,850.00</b>	<b>19,992.00</b>	<b>18,833.00</b>	<b>9,646.00</b>	<b>12,223.00</b>	<b>31,069.00</b>	<b>22,732.00</b>	<b>12,690.00</b>	<b>20,477.00</b>
Accounts & Notes Receivable	8,401.00	8,176.00	8,225.00	8,221.00	8,025.00	6,772.00	7,913.00	11,479.00	10,952.00	11,177.00	11,463.00
<b>Total Receivables</b>	<b>8,401.00</b>	<b>8,176.00</b>	<b>8,225.00</b>	<b>8,221.00</b>	<b>8,025.00</b>	<b>6,772.00</b>	<b>7,913.00</b>	<b>11,479.00</b>	<b>10,952.00</b>	<b>11,177.00</b>	<b>11,463.00</b>
Inventories	5,663.00	7,513.00	6,783.00	7,579.00	7,509.00	7,068.00	8,019.00	9,059.00	8,981.00	10,190.00	10,851.00
Prepaid Exp.	-	-	-	-	-	-	-	-	-	-	-
Restricted Cash	-	-	-	-	-	-	-	-	-	-	-
Other Current Assets	5,409.00	4,825.00	6,091.00	5,349.00	15,559.00	9,317.00	6,912.00	8,086.00	8,594.00	9,276.00	7,567.00
<b>Total Current Assets</b>	<b>55,595.00</b>	<b>43,804.00</b>	<b>38,949.00</b>	<b>41,141.00</b>	<b>49,926.00</b>	<b>32,803.00</b>	<b>35,067.00</b>	<b>59,693.00</b>	<b>51,259.00</b>	<b>43,333.00</b>	<b>50,358.00</b>
<b>Net Property, Plant &amp; Equipment</b>	<b>11,760.00</b>	<b>13,766.00</b>	<b>13,318.00</b>	<b>13,865.00</b>	<b>13,385.00</b>	<b>14,257.00</b>	<b>15,131.00</b>	<b>17,721.00</b>	<b>19,275.00</b>	<b>21,865.00</b>	<b>20,682.00</b>
Long-term Investments	17,518.00	15,999.00	7,116.00	7,015.00	2,767.00	20,147.00	20,262.00	21,526.00	15,069.00	15,368.00	2,227.00
Deferred Charges, LT	1,944.00	1,794.00	1,812.00	1,855.00	1,924.00	1,911.00	2,383.00	3,341.00	6,693.00	3,706.00	8,662.00
Other Long-Term Assets	80,749.00	92,018.00	110,420.00	107,921.00	91,420.00	98,476.00	81,386.00	79,195.00	104,909.00	142,229.00	131,467.00
<b>Total Assets</b>	<b>167,566.00</b>	<b>167,381.00</b>	<b>171,615.00</b>	<b>171,797.00</b>	<b>159,422.00</b>	<b>167,594.00</b>	<b>154,229.00</b>	<b>181,476.00</b>	<b>197,205.00</b>	<b>226,501.00</b>	<b>213,396.00</b>
<b>LIABILITIES</b>											
Accrued Exp.	1,841.00	2,359.00	2,487.00	2,196.00	2,397.00	2,390.00	3,049.00	3,332.00	3,407.00	2,776.00	3,838.00
Short-term Borrowings	5,141.00	10,159.00	10,688.00	9,953.00	8,831.00	16,464.00	3,023.00	2,690.00	3,565.00	10,877.00	7,302.00
Accounts Payable	3,210.00	3,620.00	4,536.00	4,656.00	4,674.00	3,887.00	4,283.00	5,578.00	6,809.00	6,710.00	5,633.00
Curr. Income Taxes Payable	531.00	418.00	437.00	477.00	1,265.00	980.00	1,049.00	1,266.00	1,587.00	2,349.00	2,910.00
Other Current Liabilities	10,864.00	12,842.00	12,967.00	13,145.00	14,691.00	13,583.00	14,516.00	29,806.00	26,770.00	25,082.00	23,312.00
<b>Total Current Liabilities</b>	<b>21,587.00</b>	<b>29,398.00</b>	<b>31,115.00</b>	<b>30,427.00</b>	<b>31,858.00</b>	<b>37,304.00</b>	<b>25,920.00</b>	<b>42,672.00</b>	<b>42,138.00</b>	<b>47,794.00</b>	<b>42,995.00</b>
Long-Term Debt	31,541.00	28,740.00	31,398.00	33,538.00	32,909.00	36,985.00	38,241.00	38,705.00	35,481.00	64,164.00	59,691.00
Unearned Revenue, Non-Current	-	-	-	-	-	-	-	-	-	-	-
Other Non-Current Liabilities	42,817.00	44,245.00	49,262.00	36,176.00	30,897.00	29,859.00	26,595.00	22,637.00	23,669.00	25,255.00	22,213.00
<b>Total Liabilities</b>	<b>95,945.00</b>	<b>102,383.00</b>	<b>111,775.00</b>	<b>100,141.00</b>	<b>95,664.00</b>	<b>104,148.00</b>	<b>90,756.00</b>	<b>104,014.00</b>	<b>101,288.00</b>	<b>137,213.00</b>	<b>124,899.00</b>
Pref. Stock, Non-Redeem.	29.00	26.00	24.00	21.00	19.00	17.00	-	-	-	-	-
<b>Total Pref. Equity</b>	<b>29.00</b>	<b>26.00</b>	<b>24.00</b>	<b>21.00</b>	<b>19.00</b>	<b>17.00</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
Minority Interest	321.00	278.00	296.00	348.00	351.00	303.00	235.00	262.00	256.00	274.00	294.00
Additional Paid In Capital	79,432.00	81,475.00	83,146.00	84,742.00	86,720.00	87,896.00	89,144.00	91,064.00	92,278.00	93,109.00	94,083.00
Retained Earnings	72,176.00	71,993.00	71,774.00	85,291.00	89,554.00	97,670.00	90,392.00	103,394.00	125,656.00	118,353.00	116,725.00
Treasury Stock	(73,021.00)	(79,252.00)	(84,364.00)	(89,425.00)	(101,610.00)	(110,801.00)	(110,988.00)	(111,361.00)	(113,969.00)	(114,487.00)	(114,763.00)
Comprehensive Inc. and Other	(7,316.00)	(9,522.00)	(11,036.00)	(9,321.00)	(11,276.00)	(11,639.00)	(5,310.00)	(5,897.00)	(8,304.00)	(7,961.00)	(7,842.00)
<b>Total Common Equity</b>	<b>71,592.00</b>	<b>64,972.00</b>	<b>59,816.00</b>	<b>71,635.00</b>	<b>63,739.00</b>	<b>63,429.00</b>	<b>63,473.00</b>	<b>77,462.00</b>	<b>95,917.00</b>	<b>89,288.00</b>	<b>88,497.00</b>
<b>Total Equity</b>	<b>71,621.00</b>	<b>64,998.00</b>	<b>59,840.00</b>	<b>71,656.00</b>	<b>63,758.00</b>	<b>63,446.00</b>	<b>63,473.00</b>	<b>77,462.00</b>	<b>95,917.00</b>	<b>89,288.00</b>	<b>88,497.00</b>
<b>Total Liabilities And Equity</b>	<b>167,566.00</b>	<b>167,381.00</b>	<b>171,615.00</b>	<b>171,797.00</b>	<b>159,422.00</b>	<b>167,594.00</b>	<b>154,229.00</b>	<b>181,476.00</b>	<b>197,205.00</b>	<b>226,501.00</b>	<b>213,396.00</b>
<b>Supplemental Items</b>											
Total Shares Out. on Filing Date	6,291.00	6,175.00	6,070.00	5,979.00	5,717.00	5,534.00	5,567.00	5,620.00	5,616.00	5,646.00	5,667.00
Total Shares Out. on Balance Sheet Date	6,291.00	6,175.00	6,070.00	5,979.00	5,717.00	5,534.00	5,567.00	5,620.00	5,616.00	5,646.00	5,667.00
Book Value/Share	11.33	10.48	9.81	11.92	11.09	11.41	11.36	13.74	17.03	15.77	15.56
Tangible Book Value	(5,965.00)	(23,904.00)	(47,577.00)	(33,405.00)	(25,234.00)	(19,012.00)	(14,655.00)	2,846.00	915.00	(43,667.00)	(35,735.00)
Tangible Book Value/Share	(0.95)	(3.87)	(7.84)	(5.59)	(4.41)	(3.44)	(2.63)	0.51	0.16	(7.73)	(6.31)
Total Debt	36,682.00	38,899.00	42,086.00	43,491.00	41,740.00	53,449.00	41,264.00	41,395.00	39,046.00	75,041.00	66,993.00
Net Debt	560.00	15,609.00	24,236.00	23,499.00	22,907.00	43,803.00	29,041.00	10,326.00	16,314.00	62,351.00	46,516.00
Total Minority Interest	321.00	278.00	296.00	348.00	351.00	303.00	235.00	262.00	256.00	274.00	294.00
Inventory Method	--	--	--	--	--	--	--	--	--	--	--
Raw Materials in Inventory	510.00	867.00	793.00	788.00	546.00	672.00	716.00	994.00	859.00	1,007.00	976.00
Work in Progress Inventory	3,248.00	3,932.00	3,696.00	3,908.00	4,701.00	4,131.00	4,436.00	4,424.00	5,519.00	5,688.00	6,101.00
Finished Goods Inventory	1,905.00	2,714.00	2,294.00	2,883.00	2,262.00	2,265.00	2,867.00	3,641.00	2,603.00	3,495.00	3,774.00
Other Inventory Accounts	-	-	-	-	-	-	-	-	-	-	-
Accum. Allowance for Doubtful Accts	412.00	384.00	609.00	584.00	541.00	493.00	508.00	492.00	449.00	470.00	438.00
Full Time Employees	78,300.00	97,900.00	96,500.00	90,200.00	92,400.00	88,000.00	78,500.00	79,000.00	83,000.00	88,000.00	81,000.00



Ticker: PFE US EQUITY

Sort Ascend

Period Type Annuals

Consolidated Yes

Accounting Mixed

Pfizer Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

		-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Multiples		31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022	31/12/2023	31/12/2024
TEV / LTM Total Revenue	Close	4.0x	4.4x	4.2x	4.6x	5.1x	6.4x	5.6x	4.2x	3.0x	3.8x	3.1x
	Average	3.8x	4.2x	4.4x	4.3x	4.8x	4.6x	6.0x	6.3x	3.6x	2.2x	3.7x
	High	4.1x	4.5x	5.0x	4.7x	5.5x	6.4x	6.9x	9.0x	4.0x	3.8x	4.0x
	Low	3.5x	3.9x	3.9x	4.0x	4.3x	4.0x	4.9x	4.2x	3.0x	1.6x	3.1x
TEV / LTM EBITDA	Close	10.5x	12.7x	12.5x	12.0x	13.4x	12.5x	17.6x	13.6x	7.5x	26.8x	9.8x
	Average	9.2x	11.1x	12.7x	12.8x	12.7x	12.1x	11.8x	19.8x	11.5x	5.6x	26.2x
	High	10.5x	12.7x	14.3x	13.9x	14.6x	13.5x	17.5x	28.0x	13.1x	26.8x	28.6x
	Low	8.3x	10.2x	11.3x	12.0x	11.2x	10.4x	9.7x	13.6x	7.5x	4.0x	9.8x
TEV / LTM EBIT	Close	14.9x	18.2x	18.5x	17.5x	19.5x	17.6x	28.2x	17.6x	8.7x	160.7x	15.7x
	Average	13.0x	15.8x	18.3x	19.0x	18.5x	17.6x	16.7x	31.9x	14.9x	7.0x	156.9x
	High	14.9x	18.2x	20.5x	20.5x	21.2x	19.6x	28.2x	45.0x	16.9x	160.7x	171.7x
	Low	11.9x	14.4x	16.3x	17.5x	16.3x	15.2x	13.6x	17.5x	8.7x	4.7x	15.7x
Price / LTM EPS	Close	17.5x	19.4x	15.5x	17.6x	19.3x	31.2x	19.5x	14.3x	8.3x	23.5x	11.5x
	Average	16.3x	18.0x	18.6x	15.4x	18.0x	16.8x	27.8x	22.2x	12.1x	6.0x	22.8x
	High	17.6x	19.3x	21.2x	16.8x	21.3x	29.6x	33.9x	32.4x	13.8x	23.5x	25.7x
	Low	14.9x	16.4x	14.7x	14.1x	15.5x	14.4x	19.5x	14.3x	8.3x	4.2x	11.5x
Price / Book Value	Close	2.7x	3.1x	3.3x	3.0x	3.9x	3.4x	3.2x	4.3x	3.0x	1.8x	1.7x
	Average	2.4x	2.8x	3.0x	3.3x	3.1x	3.4x	3.1x	3.7x	3.6x	2.2x	1.8x
	High	2.6x	3.0x	3.4x	3.6x	3.7x	3.8x	3.7x	5.4x	4.1x	3.0x	2.0x
	Low	2.2x	2.6x	2.6x	2.9x	2.7x	2.9x	2.4x	2.9x	3.0x	1.5x	1.6x
Price / Tangible Book Value	Close	--	--	--	--	--	--	--	116.6x	314.5x	--	--
	Average	--	--	--	--	--	--	--	116.6x	99.2x	226.6x	--
	High	--	--	--	--	--	--	--	116.6x	314.5x	314.6x	--
	Low	--	--	--	--	--	--	--	116.6x	82.4x	160.4x	--
Price / Cash Flow	Close	11.6x	13.6x	12.4x	12.9x	16.2x	17.3x	14.2x	10.2x	9.8x	18.7x	11.8x
	Average	11.1x	11.9x	13.1x	12.4x	13.2x	14.1x	15.4x	16.2x	8.6x	7.1x	18.1x
	High	12.0x	12.9x	14.9x	13.5x	15.6x	16.4x	18.8x	23.6x	9.8x	18.7x	20.4x
	Low	10.1x	10.9x	11.4x	11.3x	11.3x	12.0x	11.9x	10.2x	7.2x	5.0x	11.8x
TEV / LTM FCF	Close	12.4x	15.0x	14.0x	14.6x	18.6x	20.7x	16.8x	11.1x	11.0x	33.9x	15.3x
	Average	11.9x	12.8x	14.5x	14.0x	14.9x	16.1x	18.4x	19.2x	9.3x	8.1x	32.8x
	High	12.8x	14.2x	16.4x	15.3x	17.6x	19.6x	22.5x	27.9x	11.0x	33.9x	37.0x
	Low	10.9x	11.7x	12.6x	12.8x	12.8x	13.8x	14.3x	11.1x	7.8x	5.6x	15.3x
Dividend Yield	Close	3.3	3.5	3.7	3.6	3.2	3.7	4.2	2.7	3.1	5.7	6.4
	Average	3.3	3.3	3.6	3.7	3.5	3.7	4.2	3.7	3.2	4.4	5.9
	High	3.7	3.7	4.1	4.1	4.1	4.3	5.4	4.6	3.8	6.1	6.7
	Low	3.1	3.0	3.2	3.4	3.0	3.3	3.4	2.5	2.8	3.1	5.3







Ticker:	PFE US EQUITY	Sort	Ascend	Currency	Reporting	Change	USD
Period Type	Annuals	Consolidated	Yes	Accounting	Mixed		

Pfizer Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
<b>Pension</b>											
<b>For the Fiscal Period Ending</b>	<b>31/12/2014</b>	<b>31/12/2015</b>	<b>31/12/2016</b>	<b>31/12/2017</b>	<b>31/12/2018</b>	<b>31/12/2019</b>	<b>31/12/2020</b>	<b>31/12/2021</b>	<b>31/12/2022</b>	<b>31/12/2023</b>	<b>31/12/2024</b>
<b>Currency</b>	<b>USD</b>										
<b>Pension Net Periodic Cost</b>											
Service Cost	472.00	495.00	440.00	464.00	136.00	125.00	146.00	130.00	116.00	85.00	87.00
Interest Cost	1,148.00	1,037.00	932.00	892.00	865.00	891.00	697.00	601.00	691.00	876.00	865.00
Expected Return on Plan Assets	(1,502.00)	(1,507.00)	(1,339.00)	(1,350.00)	(1,400.00)	(1,207.00)	(1,329.00)	(1,379.00)	(1,158.00)	(1,082.00)	(1,154.00)
Pension Expense (Income)	402.00	1,203.00	696.00	695.00	(2.00)	331.00	809.00	(2,011.00)	(129.00)	(423.00)	237.00
<b>Other Postretirement Cost</b>											
Service Cost	55.00	55.00	41.00	42.00	39.00	37.00	38.00	36.00	29.00	12.00	14.00
Interest Cost	169.00	117.00	101.00	90.00	72.00	75.00	49.00	29.00	27.00	21.00	23.00
Expected Return on Plan Assets	(63.00)	(53.00)	(34.00)	(36.00)	(37.00)	(33.00)	(39.60)	(39.00)	(47.00)	(44.00)	(51.00)
Other Postretirement Benefits Expense (I	102.00	(21.00)	(59.00)	(75.00)	(111.00)	(146.00)	(282.00)	(372.00)	(578.00)	(90.00)	18.00
<b>Pension Funded Status</b>											
Fair Value of Plan Assets	21,294.00	19,592.00	20,239.00	23,147.00	21,266.00	23,542.00	25,905.00	27,075.00	17,736.00	17,487.00	16,644.00
Actual Return (Loss) on Plan Assets	1,865.00	166.00	1,632.00	2,816.00	(873.00)	3,633.00	--	--	--	--	--
Employer Contribution	493.00	1,716.00	1,360.00	1,398.00	838.00	385.00	197.00	451.00	156.00	154.00	267.00
Benefits Paid	(1,163.00)	(866.00)	(998.00)	(932.00)	(977.00)	(978.00)	(817.00)	(886.00)	(816.00)	(791.00)	(844.00)
Projected Benefit Obligation	28,852.00	25,482.00	26,687.00	28,804.00	26,373.00	28,945.00	30,307.00	28,807.00	18,917.00	18,048.00	17,144.00
Over(Under) Funded Pension	(7,558.00)	(5,890.00)	(6,448.00)	(5,657.00)	(5,107.00)	(5,403.00)	(4,402.00)	(1,732.00)	(1,181.00)	(561.00)	(500.00)
Accumulated Benefit Obligation	--	--	--	--	--	--	--	--	--	--	--
Pension Funding Ratio	73.80	76.89	75.84	80.36	80.64	81.33	85.48	93.99	93.76	96.89	97.08
<b>Other Postretirement Funded Status</b>											
Fair Value of Plan Assets	762.00	622.00	458.00	494.00	469.00	519.00	588.00	753.00	647.00	636.00	736.00
Actual Return (Loss) on Plan Assets	45.00	(3.00)	44.00	39.00	(22.00)	50.00	--	--	--	--	--
Employer Contribution	210.00	84.00	16.00	183.00	145.00	137.00	113.00	145.00	65.00	--	--
Benefits Paid	(309.00)	(300.00)	(282.00)	(280.00)	(249.00)	(221.00)	--	--	--	--	--
Projected Benefit Obligation	3,168.00	2,463.00	2,254.00	2,028.00	1,870.00	1,667.00	1,238.00	995.00	410.00	450.00	486.00
Over(Under) Funded Post Ret Benefits	(2,406.00)	(1,841.00)	(1,796.00)	(1,534.00)	(1,401.00)	(1,148.00)	(650.00)	(242.00)	237.00	186.00	250.00
Other Post-Retirement Funding Ratio	24.05	25.25	20.32	24.36	25.08	31.13	47.50	75.68	157.80	141.33	151.44
<b>Actuarial Assumptions</b>											
<b>Pension</b>											
Expected Return on Plan Assets	7.41	8.30	7.07	8.00	7.50	7.20	7.00	6.80	6.30	7.50	8.00
Discount Rate used on Plan Liabilities	3.74	4.50	3.78	3.80	4.40	3.30	2.60	2.90	5.40	5.40	5.40
Rate of Compensation Increase	2.76	2.80	2.74	2.80	2.80	--	--	--	--	--	--
<b>Other Postretirement Benefits</b>											
Expected Return on Plan Assets	8.50	8.30	8.00	8.00	7.50	7.30	7.00	6.80	6.30	7.50	8.00
Discount Rate used on Plan Liabilities	4.20	4.50	4.20	3.70	4.30	3.20	2.50	2.90	5.50	5.40	5.50
Health Care Cost Trend Projected(next y	7.00	--	--	--	--	--	--	--	--	--	--
<b>Pension Plan Asset Allocation</b>											
Fair Value of Plan Assets	21,294.00	19,592.00	20,239.00	23,147.00	21,266.00	23,542.00	25,905.00	27,075.00	17,736.00	17,487.00	16,644.00
Asset Category - Equities %	41.23	40.20	40.10	37.50	31.30	31.80	28.40	20.00	30.00	30.00	12.87
Asset Category - Debt %	34.52	35.00	34.90	39.60	47.10	48.70	50.20	60.00	60.00	50.00	50.03
Asset Category - Real Estate %	--	--	--	--	--	--	--	--	--	--	--
Asset Category - Company Stock %	--	--	--	--	--	--	--	--	--	--	--
Asset Category - Cash %	5.84	3.60	5.30	4.60	3.40	2.50	4.90	5.00	5.00	5.00	5.06
Asset Category - Other %	18.41	21.20	19.70	18.30	18.20	17.00	16.60	12.50	5.00	15.00	32.03
<b>Expected Pension Payments</b>											
Year 1	1,408.00	1,476.00	2,002.00	1,753.00	1,908.00	2,021.00	1,637.00	1,680.00	1,346.00	1,381.00	1,255.00
Year 2	1,364.00	2,124.00	1,519.00	1,573.00	1,582.00	1,560.00	1,532.00	1,527.00	1,312.00	1,268.00	1,224.00
Year 3	1,439.00	1,462.00	1,400.00	1,600.00	1,552.00	1,527.00	1,523.00	1,523.00	1,292.00	1,265.00	1,228.00
Year 4	1,540.00	1,416.00	1,421.00	1,575.00	1,518.00	1,522.00	1,521.00	1,481.00	1,280.00	1,259.00	1,210.00
Year 5	1,462.00	1,443.00	1,398.00	1,556.00	1,508.00	1,506.00	1,479.00	1,455.00	1,277.00	1,244.00	1,207.00
Beyond Year 5	7,546.00	6,988.00	6,761.00	7,479.00	7,350.00	7,186.00	7,135.00	7,032.00	6,287.00	6,077.00	5,827.00
<b>Expected Postretirement Benefits</b>											
Year 1	261.00	198.00	186.00	173.00	166.00	153.00	97.00	78.00	42.00	43.00	44.00
Year 2	211.00	205.00	196.00	179.00	171.00	137.00	94.00	73.00	43.00	45.00	47.00
Year 3	216.00	208.00	198.00	181.00	171.00	137.00	92.00	69.00	44.00	46.00	49.00
Year 4	220.00	208.00	197.00	179.00	168.00	136.00	89.00	66.00	44.00	47.00	50.00
Year 5	222.00	207.00	196.00	173.00	165.00	134.00	86.00	68.00	43.00	47.00	50.00
Beyond Year 5	1,146.00	1,001.00	919.00	802.00	777.00	642.00	430.00	359.00	192.00	218.00	245.00

